{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06483100",
            "orgStudyIdInfo": {
                "id": "24-x176"
            },
            "organization": {
                "fullName": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry",
            "officialTitle": "Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry",
            "therapeuticArea": [
                "Other"
            ],
            "study": "measurable-residual-disease-guided-post-transplant-elranatamab-maintenance-using-peripheral-blood-clonotypic-mass-spectrometry"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2031-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-25",
            "studyFirstSubmitQcDate": "2024-06-25",
            "studyFirstPostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Comprehensive Cancer Network",
                    "class": "NETWORK"
                },
                {
                    "name": "Pfizer",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Rapid Novor",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy and tolerability data for a personalized maintenance approach using peripheral blood-based clonotypic mass spectrometry MRD testing (the EasyM assay) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma"
            ],
            "keywords": [
                "Maintenance",
                "Stem cell transplant",
                "Immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 65,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Elranatamab",
                    "type": "EXPERIMENTAL",
                    "description": "Patients on elranatamab will have EasyM test every 3 months. If 2 consecutive tests are negative, will have bone marrow biopsy (BMBX) with clonoSEQ to verify MRD status. If negative, drug will be stopped \\& will go on intensive observation schedule. If testing is positive, the patient will continue drug until 2 additional tests are negative, followed by repeat BMBX. If BM MRD testing is equivocal, physician may re-test with 2nd BMBX, continue drug, or go to intensive observation. Intensive observation schedule: Blood-based MRD testing \\& disease monitoring performed monthly x 3 months, every 2 months x 6 months, \\& every 3 months until MRD recurrence or end of study (patients on-study maximum of 36 months). On observation, any positive peripheral blood MRD test (confirmed 2 weeks later) will lead to drug re-initiation. A patient may go back to observation after drug re-initiation provided 2 consecutive negative MRD tests drawn 3 months apart \\& confirmatory negative BMBX.",
                    "interventionNames": [
                        "Drug: Elrantamab",
                        "Device: EasyM",
                        "Device: clonoSEQ"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Elrantamab",
                    "description": "- Elranatamab will be dosed in 28-day cycles as follows:\n\n* C1D1: 12 mg SC priming dose\n* C1D4: 32 mg SC priming dose\n* C1D8, C1D15, C1D22: 76 mg SC\n* Cycles 2 - 6: 76 mg SC on D1 and D15\n* Cycles 7+: 76 mg SC on D1 (of 28 day cycles)",
                    "armGroupLabels": [
                        "Elranatamab"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "EasyM",
                    "description": "EasyM is a clonotypic mass spectrometry platform developed by Rapid Novor which identifies and monitors M-protein in plasma cell disorders.",
                    "armGroupLabels": [
                        "Elranatamab"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "clonoSEQ",
                    "description": "FDA approved MRD testing",
                    "armGroupLabels": [
                        "Elranatamab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Event-free survival (EFS)",
                    "description": "Includes progression, death, or treatment intolerance (discontinuation due to toxicity).",
                    "timeFrame": "Through completion of follow-up (up to 5 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "Progression-free survival (PFS) is defined as time to progression or death.",
                    "timeFrame": "Through completion of follow-up (up to 5 years)"
                },
                {
                    "measure": "Time to next therapy",
                    "description": "Time to next therapy (TTNT) is defined as the time to initiation of subsequent anti-myeloma therapy (excluding standard-of-care maintenance).",
                    "timeFrame": "Through completion of follow-up (up to 5 years)"
                },
                {
                    "measure": "Maximum depth of response by IMWG criteria",
                    "timeFrame": "Through completion of end of study visit (up to 36 months)"
                },
                {
                    "measure": "Proportion of patients achieving MRD-negativity at the 10^6 threshold per the clonoSEQ assay",
                    "description": "MRD negativity per the clonoSEQ assay will be defined as less than 1 myeloma cell per 10\\^6 bone marrow cells evaluated (i.e. \\<10-6)",
                    "timeFrame": "Through completion of end of study visit (up to 36 months)"
                },
                {
                    "measure": "Proportion of patients discontinuing therapy per MRD-guided protocol",
                    "timeFrame": "Through completion of treatment (up to 36 months)"
                },
                {
                    "measure": "Time on treatment during study period",
                    "timeFrame": "Through completion of treatment (up to 36 months)"
                },
                {
                    "measure": "Incidence and severity of treatment-related adverse events by CTCAE v5",
                    "timeFrame": "From start of treatment through 90 days after completion of treatment (up to 39 months)"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Overall survival (OS) is defined as time to death.",
                    "timeFrame": "Through completion of follow-up (up to 5 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Criteria for Pre-Screening Blood Draw\n\n* Newly diagnosed with IgG or IgA multiple myeloma (either untreated or receiving first line therapy).\n* Potentially eligible for autologous hematopoietic cell transplant (with or without tandem transplant) for frontline therapy.\n* At least 18 years of age.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. (Legally authorized representatives may sign and give informed consent on behalf of study participants.)\n\nInclusion Criteria:\n\n* Received autologous hematopoietic cell transplantation (with or without tandem transplant) as part of frontline therapy for newly diagnosed IgG or IgA multiple myeloma.\n* 80 to 140 days after AHCT with measurable disease at Day +100 landmark assessment, defined as:\n\n  * MRD-positive by clonoSEQ at \\> 10-6 myeloma cells/cell and/or\n  * Achieved less than CR\n* ECOG performance status \u2264 2\n* Adequate bone marrow and organ function within 28 days prior to start of treatment as defined below:\n\n  * Platelets \u2265 25 k/cumm\n  * Absolute neutrophil count \u2265 1.0 k/cumm; given the well-documented phenomena of lower baseline neutrophil count in patients who identify as Black or African-American (i.e. Duffy antigen null neutrophil counts, previously Benign Ethnic Neutropenia), patients who identify as Black or African American and have a stable ANC of 0.5 - 1.0 k/cumm post-AHCT may be enrolled at the discretion of the treating physician.\n  * Hemoglobin \u2265 8 g/dL without the use of growth factors or transfusion for at least 2 weeks.\n  * Total bilirubin \u2264 2 \u00d7 upper limit of normal (ULN; \u2264 3 x ULN if documented Gilbert's syndrome)\n  * Aspartate aminotransferase and alanine aminotransferase \u2264 2.5 \u00d7 ULN\n  * Creatinine clearance \u2265 30 ml/min. Patients with stable renal function and creatinine clearance of 15 - 30 ml/min may be enrolled on a case-by-case basis after discussion with the principal investigator.\n* The effects of elranatamab on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months after end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.\n\nExclusion Criteria:\n\n* Inability to identify both an EasyM clonotype and clonoSEQ ID.\n* Received \\>28 days of standard-of-care maintenance treatment following AHCT. A \u226514 day washout of standard-of-care maintenance treatment is required prior to receiving the first dose of elranatamab.\n* A history of other malignancy with the exception of non-melanoma skin cancers, low or very low risk prostate cancer by NCCN criteria status post definitive therapy or currently on active surveillance, and malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease.\n* Currently receiving any other investigational agents.\n* Prior BCMA-based treatment.\n* Presence of light chain or non-secretory disease.\n* CNS involvement of disease.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to elranatamab or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, plasma cell leukemia, POEMS syndrome, systemic amyloidosis, ongoing or active infection (bacterial, fungal, or viral).\n* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 28 days of study entry.\n* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael Slade, M.D.",
                    "role": "CONTACT",
                    "phone": "314-454-8304",
                    "email": "sladem@wustl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael Slade, M.D.",
                    "affiliation": "Washington University School of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Washington University School of Medicine",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael Slade, M.D.",
                            "role": "CONTACT",
                            "phone": "314-454-8304",
                            "email": "sladem@wustl.edu"
                        },
                        {
                            "name": "Michael Slade, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "John F DiPersio, M.D., Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Ravi Vij, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Li Ding, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Feng Gao, M.D., Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine",
                    "url": "http://www.siteman.wustl.edu"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "accessCriteria": "Interested parties should contact the investigator to discuss access to de-identified datasets."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000018365",
                    "term": "Neoplasm, Residual"
                }
            ],
            "ancestors": [
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M20497",
                    "name": "Neoplasm, Residual",
                    "asFound": "Measurable Residual Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12147",
                    "name": "Myeloma Proteins",
                    "relevance": "LOW"
                },
                {
                    "id": "M13179",
                    "name": "Paraproteins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}